NBTX stock forecast, quote, news & analysis
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients... Show more
Why Is Nanobiotix S.A. (NBTX) Stock Down -8.08% Today?
Key Takeaways
- Nanobiotix S.A. (NBTX) shares fell approximately 8.08% in the latest trading session.
- The decline followed a strong multi-week rally that pushed the stock near its 52-week high.
- No single company-specific news release drove the move; the pullback appears tied to profit-taking and technical factors.
- Broader biotech sector weakness and elevated volatility contributed to the downside.
- Investors are monitoring upcoming clinical updates and the company’s cash runway extension through early 2028.
Opening Summary
Nanobiotix S.A. (NBTX) is a clinical-stage biotechnology company focused on developing nanoparticle-based therapies, including its lead candidate NBTXR3, to enhance radiotherapy for various solid tumors. The stock closed the previous session at $46.20 before declining to approximately $42.47, representing an 8.08% drop. The move reflects a natural correction after recent gains rather than any immediate fundamental catalyst.
Technical Pullback After Recent Gains
NBTX had advanced sharply in the preceding weeks, climbing from levels below $35 to a peak above $57. The latest session saw the stock open lower and trade within a range that breached short-term support levels. Technical indicators, including moving averages and momentum oscillators, signaled potential exhaustion following the rapid ascent, prompting selling pressure from traders locking in profits.
Market Context and Trading Activity
Volume during the session exceeded typical averages for the name, consistent with heightened interest in high-beta biotech stocks. The decline occurred even as broader market indices showed mixed performance, highlighting stock-specific dynamics. Peers in the oncology and nanoparticle therapy space displayed similar intraday volatility, though NBTX underperformed the group on a relative basis. The move also coincided with a pullback from the upper end of the Bollinger Bands, reinforcing the technical nature of the reversal.
Trending AI Robots
Tickeron’s Trending AI Robots page highlights the strongest-performing AI trading bots across thousands of tickers under prevailing market conditions. The curated selection features bots with diverse strategies, timeframes, and performance metrics, allowing users to explore automated approaches tailored to individual symbols like NBTX. Market participants seeking systematic strategies can review the live rankings and performance data directly on the platform.
What Comes Next for NBTX
Investors will focus on the next clinical data readouts for NBTXR3, particularly in head-and-neck and lung cancer settings. The company has extended its cash runway into early 2028 following recent financing and partnership progress. Key risks include clinical trial timelines, regulatory decisions, and ongoing volatility typical of late-stage biotech names. Analysts continue to monitor execution on the expanded pipeline and any further updates from ongoing studies.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
NBTX in downward trend: price dove below 50-day moving average on June 02, 2026
NBTX moved below its 50-day moving average on June 02, 2026 date and that indicates a change from an upward trend to a downward trend. In of 44 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are .
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for NBTX moved out of overbought territory on May 15, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on May 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NBTX as a result. In of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for NBTX turned negative on May 21, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .
The 10-day moving average for NBTX crossed bearishly below the 50-day moving average on June 10, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NBTX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
NBTX broke above its upper Bollinger Band on May 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for NBTX entered a downward trend on June 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 69 cases where NBTX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NBTX advanced for three days, in of 225 cases, the price rose further within the following month. The odds of a continued upward trend are .
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NBTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (18.720). P/E Ratio (0.000) is within average values for comparable stocks, (36.072). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.682). NBTX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (49.505) is also within normal values, averaging (357.550).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology